[Chinese guidelines on the treatment of hemophilia (2025)]

Hemophilia is an X-linked recessive inherited hemorrhagic disease primarily caused by reduced activity or deficiency of coagulation factor Ⅷ (FⅧ) or coagulation factor Ⅸ (FⅨ). Depending on the specific coagulation factor deficiency, it is classified into two types: hemophilia A (caused by F Ⅷ deficiency) and hemophilia B (caused by F Ⅸ deficiency), each attributed to gene mutations in their respective coagulation factors. Among these, hemophilia A is the most prevalent, accounting for approximately 80% of all hemophilia cases. In recent years, the advent of novel therapeutic strategies-including long-acting coagulation factor products, non-factor therapies, and gene therapy-has ushered hemophilia into a new era of treatment. Several of these innovative products have been approved for marketing in China, marking a significant improvement in treatment outcomes for patients with hemophilia. To standardize clinical practices amid these new treatment modalities and evolving therapeutic concepts, the Thrombosis and Hemostasis Group of the Hematology Branch of the Chinese Medical Association and the Chinese Hemophilia Collaboration Group have collaborated to develop relevant guidelines. These guidelines aim to provide guidance for domestic medical professionals engaged in hemophilia diagnosis and treatment, ensuring the delivery of standardized, high-quality care.